|
There is on-going development of generic EU CTD Dossier of Sildenafil citrate, tablets, 25/50/100 mg.
DCP slot confirmed.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
|
|
Read more...
|
|
|
There is on-going development of generic EU CTD Dossier of Azithromycin dihydrate, tablets, 250/500 mg.
DCP slots will be available in November 2009.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
|
|
Read more...
|
|
|
There is on-going development of generic EU CTD Dossier of Lercanidipine, filmcoated tablets, 10/20 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
|
|
Read more...
|
|
|
There is on-going development of generic EU CTD Dossier of Irbesartan-hydrochlorothiazide, filmcoated tablets, 150+12.5/300+12.5 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
|
|
Read more...
|
|
|
There is on-going development of generic EU CTD Dossier of Repaglinide, tablets, 0.5/1/2 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
|
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 19 - 27 of 306 |
Pharma Licensing 
